Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia

ConclusionSimultaneous administration of quizartinib and CYT every other day is a promising combination regimen for AML patients with FLT3 mutations.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research